Patients with both colorectal ACF and resectable polyps
Conditions
Interventions
receive oral EPA capsule thrice 900 mg, total 2.7g per day for 1 month
receive oral placebo capsule thrice per day for 1 month
Sponsors
Yokohama City Univesity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with both colorectal ACF and resectable polyps. 2.Willingness to provide written informed consent
Exclusion criteria
Exclusion criteria: 1.History of regular use of omega-3 PUFA supplements. 2.History of regular use (defined as at least once per week) of NSAIDs and/or aspirin. 3.History of heart failure, renal failure, liver cirrhosis or chronic hepatic failure 4.History of familial adenomatous polyposis 5.History of hereditary non-polyposis colorectal cancer 6.History of inflammatory bowel disease 7.Pregnancy or possibility of pregnancy 8.Patients judged as inappropriate candidates for the trial by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the number of colorectal ACF after 1-months's intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.The drug safety 2.Mucosal fatty acid analysis 3.The cell-proliferative and apoptotic activities in the rectal epithelium and polyps 4.Laboratory data (HDL-cholesterol, LDL-cholesterol, triglycerides, fatty acid fractions, fasting blood glucose, fasting blood insulin, HbA1c, blood urea nitrogen (BUN), creatinine) 5.physical examination findings (body weight, body mass index (BMI)) | — |
Countries
Japan
Contacts
Public ContactTakuma Higurashi
Yokohama City Univesity Division of Gastroenterolgy
Outcome results
None listed